Thursday , 29 February 2024
Home Business The Covid Vaccine Windfall Turns for Pfizer and Moderna
Business

The Covid Vaccine Windfall Turns for Pfizer and Moderna


Allysia Finley

Updated Nov. 20, 2023 1:39 pm ET

The U.S. was in a fit of Covid panic during Thanksgiving week two years ago. The Omicron variant had emerged like a creature from the Black Lagoon. Public-health officials indicated we’d need another updated booster. Share prices in Pfizer and Moderna surged.

By month’s end, Pfizer’s stock-market value had surpassed $300 billion, up 50% from the start of the pandemic. Moderna’s shares had soared by more than 1,000% over the same period. In 2022 Pfizer became the first pharmaceutical company to book more than $100 billion in annual sales owing to government purchases of its vaccines and antiviral pill.

Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8



Source link

Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Related Articles

Business

The statue that moved — and the cousin I never knew

In July 1985, a number of Irish religious statues began to move. There...

Business

Think Clothes Were ‘Better’ 50 Years Ago? Our Investigation Might Surprise You

LATE LAST YEAR, old trench coats began trending on X (formerly known...

Business

The ‘Happy Dream’ of Running a Circus

When people ask me what I do for a living, and I...

Business

US carries out second strike against Houthis

Unlock the Editor’s Digest for free Roula Khalaf, Editor of the FT,...